SABCS Spotlight

According to data from a randomized phase III trial presented at the 2017 San Antonio Breast Cancer Symposium, a mix of traditional and customized acupuncture techniques were effective in reducing pain and stiffness associated with aromatase inhibitor therapy in women with early-stage breast cancer.

Christian Jackisch, MD, PhD, Professor of Obstetrics and Gynecology and Head of the Department of Obsterics and Gynaecology, Sana Klinikum Offenbach in Germany, discusses results of the GeparSepto study, as well as how a higher pathologic complete response (pCR) rate is achieved with nab-paclitaxel (Abraxane) in breast cancer.

According to findings presented at the 2017 San Antonio Breast Cancer Symposium, no significant efficacy was seen in a trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein.

Treatment with ladiratuzumab vedotin demonstrated an estimated median progression-free survival (PFS) of 11.6 weeks for patients with heavily pretreated metastatic triple-negative breast cancer (TNBC) treated  with the recommended phase II dose of the antibody–drug conjugate, according to results of a phase I study presented during the 2017 San Antonio Breast Cancer Symposium. 

Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the 5-year follow-up of the CALGB 40502 study for patients with triple-negative breast cancer (TNBC).

Treatment discontinuation due to toxicity was less frequent with olaparib (Lynparza) monotherapy compared with chemotherapy in patients with HER2-negative metastatic breast cancer and a germline <em>BRCA</em> mutation in the phase III OlympiAD study.

In findings from the phase III GeparSepto trial presented during the 2017 San Antonio Breast Cancer Symposium, long-term disease-free survival rates were improved with neoadjuvant nab-paclitaxel (Abraxane) compared with standard paclitaxel in patients with high-risk early breast cancer.

Survival rates improved with nab-paclitaxel (Abraxane) therapy compared with paclitaxel in patients with triple-negative breast cancer (TNBC) more than in other patient subsets, according to findings from a post-hoc analysis from the CALGB 40502/NCCTG N063H clinical trial.&nbsp;